SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Rapport Therapeutics Reports Q3 2026 Financials and Business Update

Rapport Therapeutics reported positive topline results from a Phase 2 trial of RAP-219 in bipolar mania; the body also references initiation of two Phase 3 trials but is truncated.

RAPP
SquawkNews Desk 1 updates Updated Nov 04, 2026, 12:20 PM UTC

Story updates

12:20:48 PM UTC
SquawkNews
RAPPORT THERAPEUTICS - REPORTS POSITIVE PHASE 2 RESULTS FOR RAP-219 IN BIPOLAR MANIA; PHASE 3 TRIALS

Related stories

Nomad Foods Q3 Adjusted Earnings Fall as Revenue Rises Nomad Foods maintained its 2026 adjusted earnings guidance. M impact | EQUITY | Nov 04, 2026, 02:01 PM UTC Scotiabank to announce fourth-quarter 2026 results Scotiabank says it will announce its fourth-quarter results on Wednesday, Dec. The announcement date is incomplete in the source. M impact | EQUITY | Nov 04, 2026, 02:00 PM UTC Voyager Technologies Wins $35M NASA HUNCH Management Contract Voyager Technologies was awarded a five-year contract to manage NASA’s HUNCH program, extending a role it has held since 2021. M impact | EQUITY | Nov 04, 2026, 02:00 PM UTC NHPC Q2 consolidated revenue from operations at 44.83 billion rupees M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC MGE Energy Reports Q3 2026 Operating Revenue of $190.4 Million M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC US Equity Futures Rise Pre-Bell as Traders Assess Midterm Election Results US equity futures rose before the bell as traders assessed the implications of a Democratic win in the US midterm elections. M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC